×
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
NASDAQ:QDEL

Quidel (QDEL) Stock Forecast, Price & News

$103.45
+3.85 (+3.87%)
(As of 05/27/2022 04:00 PM ET)
Add
Compare
Today's Range
$97.95
$103.82
50-Day Range
$89.06
$117.64
52-Week Range
$88.05
$180.06
Volume
1.84 million shs
Average Volume
640,312 shs
Market Capitalization
$4.33 billion
P/E Ratio
4.37
Dividend Yield
N/A
Beta
0.02
30 days | 90 days | 365 days | Advanced Chart
Receive QDEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Quidel and its competitors with MarketBeat's FREE daily newsletter.

Quidel logo

About Quidel

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; Savanna, an automated in vitro molecular diagnostic platform; and Virena, a wireless cellular data management and surveillance system. The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.

Headlines

Form SD QUIDEL CORP /DE/ - StreetInsider.com
See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:QDEL
CUSIP
74838J10
Employees
1,600
Year Founded
1979

Sales & Book Value

Annual Sales
$1.70 billion
Cash Flow
$20.17 per share
Book Value
$57.71 per share

Profitability

Net Income
$704.23 million
Pretax Margin
55.87%

Debt

Price-To-Earnings

Miscellaneous

Free Float
40,718,000
Market Cap
$4.33 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/04/2022
Today
5/29/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.39 out of 5 stars

Medical Sector

201st out of 1,427 stocks

Diagnostic Substances Industry

2nd out of 27 stocks

Analyst Opinion: 3.7Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Quidel (NASDAQ:QDEL) Frequently Asked Questions

Is Quidel a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quidel in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Quidel stock.
View analyst ratings for Quidel
or view top-rated stocks.

Are investors shorting Quidel?

Quidel saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,150,000 shares, an increase of 24.1% from the April 30th total of 4,150,000 shares. Based on an average trading volume of 532,200 shares, the days-to-cover ratio is presently 9.7 days. Approximately 14.0% of the company's shares are short sold.
View Quidel's Short Interest
.

When is Quidel's next earnings date?

Quidel is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Quidel
.

How were Quidel's earnings last quarter?

Quidel Co. (NASDAQ:QDEL) announced its quarterly earnings data on Wednesday, May, 4th. The company reported $11.53 earnings per share for the quarter, topping the consensus estimate of $9.17 by $2.36. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $865.05 million. Quidel had a trailing twelve-month return on equity of 56.46% and a net margin of 43.26%. The business's quarterly revenue was up 167.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $4.27 earnings per share.
View Quidel's earnings history
.

What guidance has Quidel issued on next quarter's earnings?

Quidel updated its first quarter 2022 earnings guidance on Thursday, April, 21st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $990 M-$1 billion, compared to the consensus revenue estimate of $817.30 million.

What price target have analysts set for QDEL?

3 brokerages have issued 12 month price objectives for Quidel's shares. Their forecasts range from $80.00 to $219.00. On average, they anticipate Quidel's stock price to reach $143.00 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price.
View analysts' price targets for Quidel
or view top-rated stocks among Wall Street analysts.

Who are Quidel's key executives?
Quidel's management team includes the following people:
  • Mr. Douglas C. Bryant, Pres, CEO & Director (Age 64, Pay $1.41M) (LinkedIn Profile)
  • Mr. Randall J. Steward, Chief Financial Officer (Age 68, Pay $733.08k)
  • Mr. Robert J. Bujarski, Chief Operating Officer (Age 54, Pay $770.62k)
  • Ms. Michelle A. Hodges, Sr. VP & Gen. Counsel (Age 62, Pay $620.61k)
  • Dr. Werner Kroll, Sr. VP of R&D (Age 65, Pay $758.22k)
  • Ruben Argueta, Director of Investor Relations
  • Mr. Ratan S. Borkar, Sr. VP of International Commercial Operations (Age 48)
  • Mr. Michael Donald Abney Jr., Sr. VP of North American Sales & Distribution (Age 58)
  • Mr. Edward Keith Russell, Sr. VP of Bus. Devel. (Age 54)
  • Ms. Karen C. Gibson, Sr. VP of Digital Health Bus. Unit (Age 60)
What is Doug Bryant's approval rating as Quidel's CEO?

47 employees have rated Quidel CEO Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among Quidel's employees.

What other stocks do shareholders of Quidel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quidel investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Square (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM).

What is Quidel's stock symbol?

Quidel trades on the NASDAQ under the ticker symbol "QDEL."

Who are Quidel's major shareholders?

Quidel's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.21%), BlackRock Inc. (7.71%), State Street Corp (2.64%), Wellington Management Group LLP (2.29%), Dimensional Fund Advisors LP (1.46%) and Bank of New York Mellon Corp (0.90%). Company insiders that own Quidel stock include Charles P Slacik, Douglas C Bryant, Edward L Michael, Mary Lake Ph D Polan, Matthew Strobeck, Michael Donald Jr Abney, Randall J Steward, Werner Kroll, William J Ferenczy and William J Ferenczy.
View institutional ownership trends for Quidel
.

Which major investors are selling Quidel stock?

QDEL stock was sold by a variety of institutional investors in the last quarter, including LGT Capital Partners LTD., Wellington Management Group LLP, Invesco Ltd., Russell Investments Group Ltd., Twin Tree Management LP, New York State Common Retirement Fund, JPMorgan Chase & Co., and BlackRock Inc..
View insider buying and selling activity for Quidel
or view top insider-selling stocks.

Which major investors are buying Quidel stock?

QDEL stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Los Angeles Capital Management LLC, Simcoe Capital Management LLC, State Street Corp, Pacer Advisors Inc., and Nordea Investment Management AB. Company insiders that have bought Quidel stock in the last two years include Douglas C Bryant, Edward L Michael, and Matthew Strobeck.
View insider buying and selling activity for Quidel
or or view top insider-buying stocks.

How do I buy shares of Quidel?

Shares of QDEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quidel's stock price today?

One share of QDEL stock can currently be purchased for approximately $103.45.

How much money does Quidel make?

Quidel has a market capitalization of $4.33 billion and generates $1.70 billion in revenue each year. The company earns $704.23 million in net income (profit) each year or $23.69 on an earnings per share basis.

How many employees does Quidel have?

Quidel employs 1,600 workers across the globe.

When was Quidel founded?

Quidel was founded in 1979.

What is Quidel's official website?

The official website for Quidel is www.quidel.com.

How can I contact Quidel?

Quidel's mailing address is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. The company can be reached via phone at (858) 552-1100, via email at [email protected], or via fax at 858-453-4338.

This page was last updated on 5/29/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.